We’re proud to announce the launch of our new service offering: Medical Device Testing!
June 16, 2025

👉 www.pharmidex.com/medical-device-testing-services


With over 23 years of experience in preclinical R&D, we’re expanding our capabilities to support the development and regulatory testing of innovative medical devices from biocompatibility assessments to in vitro and in vivo efficacy models.


This new service allows us to collaborate even more closely with biotech companies, CRO partners, academic innovators and medical device startups helping bring safe, effective and transformative technologies to patients faster.


Whether you're exploring a novel implant, delivery system, or diagnostic platform, our team is ready to support you at every step with the same scientific integrity and agility that Pharmidex is known for.


💡 Let’s accelerate innovation, together.


#MedicalDevices #Pharmidex #DrugDevelopment #MedicalDeviceTesting #Biotech #ScientificInnovation #RegulatorySupport #LifeSciences

🚀 Pharmidex at the R&D Society Life Science Workshop!

June 11, 2025
Pharmidex team are delighted to participate in workshop on "Re-shaping UK life science commercialisation strategy" organised by The Research and Development Society on Wednesday 11th June, at Mereside, Alderley Park. If you are attending, please linkup with our colleague Mo Alavijeh who will be delighted to meet you. Jamie Phadke , Alderley Park #UKlifescience https://lnkd.in/e6uKsRcN

🔬 Pharmidex at the 4th RSC Anglo-Nordic Medicinal Chemistry Symposium

June 10, 2025
Martin Barrett , Head of Business Development, will attend the symposium on 10–13 June 2025 at Hotel Comwell Borupgaard, Denmark. The event gathers top European scientists to discuss drug discovery. Martin looks forward to connecting with academia, CROs, and pharma to explore collaborations and showcase Pharmidex’s services from in silico to in vivo pharmacology. Attending? Let’s connect! 🔗 https://lnkd.in/ev7TW7WG

🔬 Pharmidex is proud to contribute to new research!

June 10, 2025
We’re excited to announce our involvement in the recent publication: "Anti-Inflammatory Activity of Ensifentrine: A Novel, Selective Dual Inhibitor of PDE3 and PDE4" 📄 https://pubmed.ncbi.nlm.nih.gov/40245851/ 📄 https://www.pharmidex.com/publications-by-pharmidex Dr. Radhakrishnan Venkatasamy , our Senior Scientist in autoinflammatory and immune diseases, co-authored this study highlighting Ensifentrine’s anti-inflammatory potential. This reflects Pharmidex’s commitment to advancing therapies through expert science and collaboration.
More Posts